Showing 683 results
-
Media Release /Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo(1)…
-
Media Release /
-
Media Release /BEOVU (brolucizumab-dbll) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one…
-
Media Release /
-
Media Release /Black women with breast cancer are approximately 40% more likely to die compared to white women with breast cancer in the U.S.[1] - and are also more likely to be diagnosed at a later stage with…
-
Media Release /
-
Media Release /In KESTREL and KITE, BEOVU (brolucizumab-dbll) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in…
-
Media Release /At least 75% of children six years and older achieved PASI 90 at Week 52 when treated with Cosentyx in two pivotal studies1,2 Majority of children experienced improved health-related quality of…
-
Media Release /Kesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients…
-
Media Release /New post hoc data from the Phase III EXPAND trial showed combined high levels of plasma neurofilament light chain (NfL) and plasma glial fibrillary acidic protein (GFAP) were consistently…
